TP53 and neoplasm: As such, ΔN variants act as survival factors that confer drug resistance to tumor cells expressing wild-type p53 or p63/p73 by counteracting the growth-suppressive and cell death–inducing properties of p53 and p63/p73 [11, 18–20].